Novel peptides for the diagnosis of schizophrenia
CA 2441925 C · Owner: Deckmann, Michael (Deceased) · Inventors: Deckmann, Michael (Deceased)
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Short peptides are provided, which bind to a body fluid sample obtained from a schizophrenic patient at a substantively higher level than to a body fluid sample obtained from a non-schizophrenic individual. The peptides are no more than 10 amino acids long and comprise a continuous sequence of at least 5 amino acids which consists of at least one positively charged amino acid at one of its ends. The provided peptides which are the putative binding sites , of autoantibodies found in high levels in schizophrenic individuals are thus , useful in diagnosis of schizophrenia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 21, 2002 and granted July 31, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 21, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 21, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.